Crofab Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical effectiveness of crofab, established emergency protocols for snakebites, increased outdoor exposure risks, hospital emergency preparedness, government supported antivenom stocking.

The growth in the forecast period can be attributed to expansion of emergency care access, rising awareness of snakebite management, improved rural healthcare reach, government investment in antivenom programs, advancements in biologic antitoxin production. Major trends in the forecast period include sustained demand for snakebite antivenom, rising focus on emergency envenomation treatment, expansion of trauma and emergency care infrastructure, improved availability of targeted antivenoms, growing awareness of rapid snakebite intervention.

The rising incidence of snakebites is expected to drive the growth of the crofab market in the coming years. Snakebite incidents occur when individuals are bitten by snakes, whether venomous or non-venomous. This increase is due to factors such as greater human encroachment into wildlife habitats, climate change affecting snake behavior and habitats, expanding rural populations in endemic areas, and more outdoor recreational activities in snake-prone regions. Carofab provides rapid and effective treatment for snakebites by neutralizing venom toxins, preventing severe complications, and reducing the risk of death, thereby improving patient outcomes in critical situations. For example, in October 2023, the National Library of Medicine reported that in Australia, approximately 3,000 snakebites occur annually, resulting in around 500 hospitalizations and an average of two fatalities per year. Consequently, the rising incidence of snakebites is driving growth in the crofab market.

The increasing number of emergency care facilities is expected to support the expansion of the crofab market. Emergency care facilities are healthcare establishments that provide immediate medical attention for acute illnesses or injuries requiring urgent intervention. The growth in these facilities is driven by rising incidences of chronic and acute conditions, improved access to healthcare, and the need for timely medical interventions during critical emergencies. CroFab, an antivenom specifically designed to treat venomous snakebites from North American pit vipers, enhances the capabilities of emergency care facilities by enabling rapid and effective neutralization of venom, reducing symptom severity, preventing complications, and improving patient outcomes. For instance, in September 2023, the Royal College of Emergency Medicine, a UK-based professional association, reported that A&E departments across England recorded approximately 25.3 million attendances in 2022/23, reflecting a 4% increase compared to the previous year. Therefore, the growth in emergency care facilities is driving the crofab market.

The rising healthcare expenditure is expected to further propel the growth of the crofab market. Healthcare expenditure refers to the total spending on medical services, products, and infrastructure over a specific period. This increase is driven by factors such as an aging population, higher prevalence of chronic diseases, advancements in medical technology, rising pharmaceutical costs, and broader access to healthcare services. Increased healthcare expenditure supports CroFab by funding research, production, and distribution of this life-saving snakebite antivenom, ensuring accessibility while promoting ongoing medical advancements and sustaining healthcare systems. For example, in May 2024, the Office for National Statistics, a UK-based government department, reported that healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with 0.9% growth in 2022. As a result, rising healthcare expenditure is driving growth in the crofab market.

Major companies operating in the crofab market are SERB Specialty Pharmaceuticals.

North America was the largest region in the crofab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crofab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the crofab market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately influenced the crofab market by increasing costs related to biologic antivenom production, cold chain storage, and emergency distribution logistics. These impacts are most apparent in hospital emergency departments and trauma centers. Higher tariffs have placed pressure on public and private procurement budgets. At the same time, tariffs are encouraging domestic biologics manufacturing initiatives. This supports long term resilience of antivenom supply chains.

The crofab market research report is one of a series of new reports that provides crofab market statistics, including crofab industry global market size, regional shares, competitors with a crofab market share, detailed crofab market segments, market trends and opportunities, and any further data you may need to thrive in the crofab industry. This crofab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Crofab is a snakebite antivenom used to treat envenomation from pit vipers, including rattlesnakes, copperheads, and cottonmouths. It is administered intravenously to neutralize venom and reduce symptoms such as swelling, pain, and potential organ damage.

The main indications for Crofab include hemotoxic effects, local tissue damage, and systemic toxicity. Hemotoxic effects involve the venom’s impact on the blood and cardiovascular system, including destruction of red blood cells, interference with blood clotting, and damage to blood vessels. Crofab is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies, serving end users such as hospitals, clinics, ambulatory care, and home care.

The crofab market consists of sales of products including antigen-binding fragment (Fab), and polyclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.